Literature DB >> 34697155

Synergistic Effects of BTK Inhibitor HM71224 and Methotrexate in a Collagen-induced Arthritis Rat Model.

Kyung Jin Choi1,2, Yu-Yon Kim2, Sun Young Jang2, Young Gil Ahn2, Kwee Hyun Suh2, Young Hoon Kim3, Hyung Sik Kim4.   

Abstract

BACKGROUND/AIM: Using a rat model of collagen-induced arthritis (CIA), we evaluated the therapeutic effects of HM71224 (BTKi), as well as the drug-drug interactions in combined therapy with methotrexate (MTX) based on both drugs' pharmacological role in immune regulation and antiinflammation.
MATERIALS AND METHODS: Arthritis in rats was induced using type II collagen and incomplete Freund's adjuvant. The therapeutic effects of HM71224 (alone or in combination with MTX) were evaluated by arthritis score, paw volume, body weight, and histopathological examination (H&E and Safranin-O staining). The drug-drug interactions between HM71224 and MTX were investigated by measuring plasma, liver enzyme and creatinine levels and blood cell counts.
RESULTS: HM71224 reduced the clinical signs of arthritis, paw volume, and body weight loss in CIA rats. ED50 and ED90 were 1.0 and 2.5 mg/kg, respectively. HM71224 combined with MTX decreased the arthritis score, bone erosion, synovitis, and cartilage degradation without apparent interaction.
CONCLUSION: The combination of HM71224 and MTX improved the therapeutic effect with no drug-drug interactions in RA.
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Arthritis; BTK inhibitor; HM71224; collagen-induced arthritis; methotrexate

Mesh:

Substances:

Year:  2021        PMID: 34697155      PMCID: PMC8627762          DOI: 10.21873/invivo.12619

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  21 in total

1.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

2.  Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.

Authors:  Vivian P Bykerk; Pooneh Akhavan; Glen S Hazlewood; Orit Schieir; Anne Dooley; Boulos Haraoui; Majed Khraishi; Sharon A Leclercq; Jean Légaré; Diane P Mosher; James Pencharz; Janet E Pope; John Thomson; Carter Thorne; Michel Zummer; Claire Bombardier
Journal:  J Rheumatol       Date:  2011-09-15       Impact factor: 4.666

3.  RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.

Authors:  Daigen Xu; Yong Kim; Jennifer Postelnek; Minh Diem Vu; Dong-Qing Hu; Cheng Liao; Mike Bradshaw; Jonathan Hsu; Jun Zhang; Achal Pashine; Dinesh Srinivasan; John Woods; Anita Levin; Alison O'Mahony; Timothy D Owens; Yan Lou; Ronald J Hill; Satwant Narula; Julie DeMartino; Jay S Fine
Journal:  J Pharmacol Exp Ther       Date:  2012-01-06       Impact factor: 4.030

4.  Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1 beta to the interleukin 1 receptor on target cells.

Authors:  M Brody; I Böhm; R Bauer
Journal:  Eur J Clin Chem Clin Biochem       Date:  1993-10

5.  Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone.

Authors:  R I Fox; S L Morgan; H T Smith; B A Robbins; M G Choc; J E Baggott
Journal:  Rheumatology (Oxford)       Date:  2003-04-16       Impact factor: 7.580

6.  Dual functions of Bruton's tyrosine kinase and Tec kinase during Fcgamma receptor-induced signaling and phagocytosis.

Authors:  Jenny Jongstra-Bilen; Adrianet Puig Cano; Manvi Hasija; Haiyan Xiao; C I Edvard Smith; Myron I Cybulsky
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

7.  Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.

Authors:  Andrew L Rankin; Nilufer Seth; Sean Keegan; Tatyana Andreyeva; Tim A Cook; Jason Edmonds; Nagappan Mathialagan; Micah J Benson; Jameel Syed; Yutian Zhan; Stephen E Benoit; Joy S Miyashiro; Nancy Wood; Shashi Mohan; Elena Peeva; Shashi K Ramaiah; Dean Messing; Bruce L Homer; Kyri Dunussi-Joannopoulos; Cheryl L Nickerson-Nutter; Mark E Schnute; John Douhan
Journal:  J Immunol       Date:  2013-09-25       Impact factor: 5.422

Review 8.  Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis.

Authors:  J A M Wessels; T W J Huizinga; H-J Guchelaar
Journal:  Rheumatology (Oxford)       Date:  2007-11-28       Impact factor: 7.580

9.  Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. A possible mechanism of reduced hepatotoxicity.

Authors:  P Seideman; F Albertioni; O Beck; S Eksborg; C Peterson
Journal:  Arthritis Rheum       Date:  1994-06

10.  Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate.

Authors:  Shankar Revu; Petra Neregård; Erik af Klint; Marina Korotkova; Anca Irinel Catrina
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.